Edouard Bingen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edouard Bingen has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
N Lambert-Zechovsky
12 shared publications- Y. Aujard
Laboratoire de microbiologie, hôpital Robert-Debré, assistance publique-hôpitaux de Paris, 48, boulevard Sérurier, 75019 Paris, France
12 shared publications Philippe Bidet
Université Paris VII, UFR Médicale; EA 3105, Laboratoire d'Etudes de Génétique Bactérienne dans les Infections de l'Enfant; Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Microbiologie, Hôpital Robert Debré, Paris, France
11 shared publicationsOlivier Clermont
Laboratoire d'études de génétique bactérienne dans les infections de l'enfant (EA3105), Université Denis Diderot—Paris 7, Service de Microbiologie, Hôpital Robert Debré (AP-HP), 75019 Paris, France
10 shared publications- Antoine Bourrillon
APHP-University Hospital R. Debré, Paris, France, France
9 shared publications C Doit
APHP-University Hospital R. Debré, Paris, France, France
9 shared publications
Latest Publications
- 31 December 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (12) , 1284-1289
Parotidite bactérienne aiguë chez les nourrissons de moins de 3mois : étude rétrospective dans un centre hospitalier universitaire
- 31 December 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (12) , 1284-1289
Parotidite bactérienne aiguë chez les nourrissons de moins de 3mois : étude rétrospective dans un centre hospitalier universitaire
- 1 November 2010
- Published by Springer Nature in Pediatric Research
- Vol. 68 (1) , 125
240 Factors Influencing Neurological Outcome of Children with Bacterial Meningitis
- 1 November 2010
- Published by Springer Nature in Pediatric Research
- Vol. 68 (1) , 125
240 Factors Influencing Neurological Outcome of Children with Bacterial Meningitis
- 30 June 2008
- Published by Elsevier in Archives de Pédiatrie
- Vol. 15 (5) , 543-544
Méningites à Pneumocoque : Impact du vaccin antipneumococcique heptavalent conjugué
- 30 June 2008
- Published by Elsevier in Archives de Pédiatrie
- Vol. 15 (5) , 543-544
Méningites à Pneumocoque : Impact du vaccin antipneumococcique heptavalent conjugué
- 30 November 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 27 (3) , 191-199
Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation
The French Pediatric Infectious Diseases Group set up an active surveillance network to analyze the clinical and biological features of pneumococcal meningitis and the impact of the seven-valent pneumococcal conjugate vaccine (PCV7). From 2001 to 2005, 234 pediatric wards working with 166 microbiology laboratories enrolled all children with pneumococcal meningitis. Risk factors, signs and symptoms, vaccination status, cerebrospinal fluid analysis, treatments and case fatality rates were recorded. One hundred and sixty-nine centers (169/234) reported 616 cases, median age was 0.9 years and 67.2% of children were < or =2 years old. Underlying conditions were present in 13.1% of cases. The proportion of penicillin non-susceptible strains was 48.7%. Vancomycin plus a third-generation cephalosporin was prescribed in 92.7% of cases, and steroids were given before antibiotic treatment in 16.5% of cases. The case fatality rate was 10.8% overall and was not related to age, antibiotic susceptibility or steroid use. In children 2 to 24 months old compared to the prevaccinal period (2001-2002) a decrease of 28.4% of the number of cases was observed in 2005 (P < 0.05). Among children 2 to 24 months old, the proportion of serotypes covered by the PCV7 fell from 39/57 (68.4%) in 2001-2002 to 19/45 (42.2%) in 2005, while the proportion of non-vaccine serotypes and related serotypes increased respectively from 9/57 (15.8%) and 9/57 (15.8%) in 2001-2002 to 14/45 (31.1%) and 12/45 (26.7%) in 2005. Among 52 cases of pneumococcal meningitis that have occurred in vaccinated children (> or =1 dose) with PCV7, 7 were due by vaccine serotypes. This study provides data on underlying conditions, penicillin susceptibility, serotype evolution according to vaccination status and risk factors for mortality for pneumococcal meningitis in children from 2001-2005 in France.
- 30 November 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 27 (3) , 191-199
Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation
The French Pediatric Infectious Diseases Group set up an active surveillance network to analyze the clinical and biological features of pneumococcal meningitis and the impact of the seven-valent pneumococcal conjugate vaccine (PCV7). From 2001 to 2005, 234 pediatric wards working with 166 microbiology laboratories enrolled all children with pneumococcal meningitis. Risk factors, signs and symptoms, vaccination status, cerebrospinal fluid analysis, treatments and case fatality rates were recorded. One hundred and sixty-nine centers (169/234) reported 616 cases, median age was 0.9 years and 67.2% of children were < or =2 years old. Underlying conditions were present in 13.1% of cases. The proportion of penicillin non-susceptible strains was 48.7%. Vancomycin plus a third-generation cephalosporin was prescribed in 92.7% of cases, and steroids were given before antibiotic treatment in 16.5% of cases. The case fatality rate was 10.8% overall and was not related to age, antibiotic susceptibility or steroid use. In children 2 to 24 months old compared to the prevaccinal period (2001-2002) a decrease of 28.4% of the number of cases was observed in 2005 (P < 0.05). Among children 2 to 24 months old, the proportion of serotypes covered by the PCV7 fell from 39/57 (68.4%) in 2001-2002 to 19/45 (42.2%) in 2005, while the proportion of non-vaccine serotypes and related serotypes increased respectively from 9/57 (15.8%) and 9/57 (15.8%) in 2001-2002 to 14/45 (31.1%) and 12/45 (26.7%) in 2005. Among 52 cases of pneumococcal meningitis that have occurred in vaccinated children (> or =1 dose) with PCV7, 7 were due by vaccine serotypes. This study provides data on underlying conditions, penicillin susceptibility, serotype evolution according to vaccination status and risk factors for mortality for pneumococcal meningitis in children from 2001-2005 in France.
- 1 June 2007
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (6) , 2002-2004
Molecular Epidemiology of the sil Streptococcal Invasive Locus in Group A Streptococci Causing Invasive Infections in French Children
We found 31 different emm -toxin genotypes among 74 group A streptococcal isolates causing invasive infections in French children. The predominant emm types were emm 1 (25%), emm 3 (8%), emm 4 (8%), emm 6 (7%), and emm 89 (9%). Sixteen percent of isolates harbored the streptococcal invasive locus, half of them belonging to emm 4.
- 1 June 2007
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (6) , 2002-2004
Molecular Epidemiology of the sil Streptococcal Invasive Locus in Group A Streptococci Causing Invasive Infections in French Children
We found 31 different emm -toxin genotypes among 74 group A streptococcal isolates causing invasive infections in French children. The predominant emm types were emm 1 (25%), emm 3 (8%), emm 4 (8%), emm 6 (7%), and emm 89 (9%). Sixteen percent of isolates harbored the streptococcal invasive locus, half of them belonging to emm 4.
- 1 April 2007
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 73 (7) , 2373-2377
Detection and Identification by PCR of a Highly Virulent Phylogenetic Subgroup among Extraintestinal Pathogenic Escherichia coli B2 Strains
Closely related Escherichia coli B2 strains O1:K1, O2:K1, O18:K1, and O45:K1 constitute a major subgroup causing extraintestinal infections. A DNA pathoarray analysis was used to develop a PCR specific for this subgroup that was included in the multiplex phylogenetic-grouping PCR method. Our PCR may serve to identify this virulent subgroup among different ecological niches.
- 1 April 2007
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 73 (7) , 2373-2377
Detection and Identification by PCR of a Highly Virulent Phylogenetic Subgroup among Extraintestinal Pathogenic Escherichia coli B2 Strains
Closely related Escherichia coli B2 strains O1:K1, O2:K1, O18:K1, and O45:K1 constitute a major subgroup causing extraintestinal infections. A DNA pathoarray analysis was used to develop a PCR specific for this subgroup that was included in the multiplex phylogenetic-grouping PCR method. Our PCR may serve to identify this virulent subgroup among different ecological niches.
- 1 November 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (11) , 4204-4207
First Detection of the Ambler Class C 1 AmpC β-Lactamase in Citrobacter freundii by a New, Simple Double-Disk Synergy Test
We report on the first detection of an AmpC-type Ambler class C 1 (ACC-1) beta-lactamase in Citrobacter freundi isolated from a patient also harboring ACC-1-producing Escherichia coli and Klebsiella pneumoniae. We propose a simple cefoxitin-based double-disk synergy test (DDST) for the specific detection of ACC-1 in members of the family Enterobacteriaceae, including natural AmpC producers, in association with a cloxacillin-based DDST as a first-line AmpC-type beta-lactamase screening test.
- 1 November 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (11) , 4204-4207
First Detection of the Ambler Class C 1 AmpC β-Lactamase in Citrobacter freundii by a New, Simple Double-Disk Synergy Test
We report on the first detection of an AmpC-type Ambler class C 1 (ACC-1) beta-lactamase in Citrobacter freundi isolated from a patient also harboring ACC-1-producing Escherichia coli and Klebsiella pneumoniae. We propose a simple cefoxitin-based double-disk synergy test (DDST) for the specific detection of ACC-1 in members of the family Enterobacteriaceae, including natural AmpC producers, in association with a cloxacillin-based DDST as a first-line AmpC-type beta-lactamase screening test.
- 1 October 2006
- p. S17-21
[Two cases of Pseudomonas aeruginosa neonatal meningitis treated by ciprofloxacine].
Two cases of Pseudomonas aeruginosa neonatal meningitis are reported. Case 1 occurred on day 6 of life, at home, in a full term newborn. Favourable outcome was obtained with a treatment associating ceftazidime, 21 days, gentamicin, 10 days and ciprofloxacin, 10 days. Case no 2 was a nosocomial meningitis in a 32 weeks and 4 days gestational age premature newborn. Despite in vitro effective antibiotherapy with ceftazidime, netilmicine and ciprofloxacine, six cerebral abscesses were observed during the second week of treatment. Ceftazidime was stopped after 6 weeks and ciprofloxacine prolonged until neuroradiological cure of cerebral lesions at one year of age. Normal outcome was observed at 3 and 4 and half year of age. Therapeutic indications and clinical tolerance of ciprofloxacine in neonatal meningitis are discussed.
- 1 October 2006
- p. S17-21
[Two cases of Pseudomonas aeruginosa neonatal meningitis treated by ciprofloxacine].
Two cases of Pseudomonas aeruginosa neonatal meningitis are reported. Case 1 occurred on day 6 of life, at home, in a full term newborn. Favourable outcome was obtained with a treatment associating ceftazidime, 21 days, gentamicin, 10 days and ciprofloxacin, 10 days. Case no 2 was a nosocomial meningitis in a 32 weeks and 4 days gestational age premature newborn. Despite in vitro effective antibiotherapy with ceftazidime, netilmicine and ciprofloxacine, six cerebral abscesses were observed during the second week of treatment. Ceftazidime was stopped after 6 weeks and ciprofloxacine prolonged until neuroradiological cure of cerebral lesions at one year of age. Normal outcome was observed at 3 and 4 and half year of age. Therapeutic indications and clinical tolerance of ciprofloxacine in neonatal meningitis are discussed.
- Open Access
- 1 March 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (3) , 1156-1158
Comparative Prevalence of Virulence Factors in Escherichia coli Causing Urinary Tract Infection in Male Infants with and without Bacteremia
Escherichia coli isolates causing urinary tract infection in 83 male infants younger than 90 days with and without bacteremia were compared for phylogenetic groups and the presence of 10 virulence factors. Our result suggest that the absence of both hemolysin and antigen K1 may be used as a negative predictive factor for bacteremia.
- 1 March 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (3) , 1156-1158
Open AccessComparative Prevalence of Virulence Factors in Escherichia coli Causing Urinary Tract Infection in Male Infants with and without Bacteremia
Escherichia coli isolates causing urinary tract infection in 83 male infants younger than 90 days with and without bacteremia were compared for phylogenetic groups and the presence of 10 virulence factors. Our result suggest that the absence of both hemolysin and antigen K1 may be used as a negative predictive factor for bacteremia.
- Open Access
- 1 October 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (7) , 1059-1063
Bacterial Meningitis in Children: A French Prospective Study
We are grateful to P. d'Athis (Dijon University, Dijon, France), P. Bidet (Robert Debré Hospital, Paris, France), N. Kohn, S. Tortorreli, and E. Taieb, for tech
- 1 October 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (7) , 1059-1063
Open AccessBacterial Meningitis in Children: A French Prospective Study
We are grateful to P. d'Athis (Dijon University, Dijon, France), P. Bidet (Robert Debré Hospital, Paris, France), N. Kohn, S. Tortorreli, and E. Taieb, for tech